EMAIL-HFHot Line 5Digital Health
Digital Strategy for Implementing SGLT2 Inhibitors in Heart Failure
Implementation of sodium-glucose co-transporter 2 inhibitors in heart failure through a digital strategy
Presenting authorMariam ElmegaardHeart Failure / Cardiomyopathy · Herlev HospitalMariam Elmegaard, MD, PhD, is a physician and cardiovascular researcher at Copenhagen University Hospital – Herlev and Gentofte and the University of Copenhagen, Denmark. She obtained her PhD in cardiovascular epidemiology from the University of Copenhagen in 2026. Her research focuses on heart failure, cardiovascular epidemiology, clinical trials, implementation science, and translating evidence-based cardiovascular therapies into routine clinical practice.
Overview
Pending results of this digital SGLT2i implementation trial in HF leave open whether technology improves uptake.
Key result
A digital strategy for the implementation of sodium-glucose co-transporter 2 inhibitors in heart failure is being evaluated, with trial results currently pending.
Discussion
Expert reaction lands here the moment EMAIL-HF reports.
Key Points
- The late-breaking trial evaluates whether a digital strategy enhances the clinical implementation of sodium-glucose co-transporter 2 inhibitors.
- Late-breaking clinical trial presented at ESC Congress 2026 examines digital strategy deployment for patient management in heart failure care.
- Findings highlight the potential of digital healthcare pathways to optimize sodium-glucose co-transporter 2 inhibitors uptake with results pending.
Main Result
Absolute Event Rate: 0% vs 0%